SCHEMBL6088062

SCHEMBL6088062

CCNc1ccccc1C(C)=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 2/20 0.48
JAK1 P23458 2/20 0.48
FABP4 P15090 1/20 0.47
PDK1 Q15118 1/20 0.46
PDK2 Q15119 1/20 0.46
PDK3 Q15120 1/20 0.46
PDK4 Q16654 1/20 0.46
AKR1C3 P42330 1/20 0.46
AKR1C2 P52895 1/20 0.46
KDM4E B2RXH2 2/20 0.46
GLA P06280 1/20 0.46
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CNR2 P34972 1/20 0.44
GAA P10253 1/20 0.44
AGTR1 P30556 1/20 0.43
RAB9A P51151 1/20 0.43
IDO1 P14902 1/20 0.43
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2001238 0.86 FABP4 (0.48) JAK2JAK1FABP4KDM4EGLA
SCHEMBL14470975 0.85 KDM4E (0.51) PDK1PDK2PDK3PDK4AKR1C3
SCHEMBL184136 0.84 ALDH1A1 (0.62) FABP4AKR1C3AKR1C2KDM4EALDH1A1
SCHEMBL11520956 0.82 FABP4 (0.49) JAK2JAK1FABP4KDM4EGLA
SCHEMBL4184556 0.82 KDM4E (0.46) JAK2JAK1FABP4KDM4EGLA
SCHEMBL3441356 0.82 AGTR1 (0.54) JAK2JAK1KDM4EALDH1A1HPGD
SCHEMBL7023135 0.82 JAK2 (0.43) JAK2JAK1FABP4PDK1PDK2
SCHEMBL2492869 0.81 IDO1 (0.47) JAK2JAK1FABP4KDM4EGLA
SCHEMBL1903514 0.81 KDM4E (0.70) KDM4EGLAALDH1A1HSD17B10GAA
Hydrochloric Acid SCHEMBL2955045 0.81 KDM4E (0.45) JAK2JAK1FABP4KDM4EGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7560565-B2 Method for preparing derivatives of 3-hydroxypicolinic acid BAYER CROPSCIENCE SA (FR) 2009-07-14 US disclosed
US-20080146616-A1 Indoles Useful in the Treatment of Inflammation BIOLIPOX AB (SE) 2008-06-19 US disclosed
US-6998489-B2 Methods of making indazoles ALCON, INC. (CH) 2006-02-14 US disclosed
EP-1392659-A4 METHODS OF MAKING INDAZOLES ALCON INC (CH) 2004-10-20 EP disclosed
US-20040142998-A1 Methods of making indazoles ALCON, INC. (CH) 2004-07-22 US disclosed
EP-1392659-A1 METHODS OF MAKING INDAZOLES Alcon, Inc. (CH) 2004-03-03 EP disclosed
WO-2002098862-A1 METHODS OF MAKING INDAZOLES ALCON, INC. (CH) 2002-12-12 WO disclosed
WO-2002098861-A1 METHODS OF MAKING 1-(2-AMINOPROPYL)-6-HYDROXYINDAZOLE ALCON, INC. (CH) 2002-12-12 WO disclosed
EP-0343574-B1 4(1H)-quinolone derivatives KIRIN BREWERY (JP) 1994-07-27 EP disclosed
US-5081121-A Cardiotonic agents KIRIN BEER KABUSHIKI KAISHA (JP) 1992-01-14 US disclosed
US-4997840-A Quinolone sulphonates having antihypertensive activity THE BOOTS COMPANY, PLC (GB) 1991-03-05 US disclosed
EP-0343574-A1 4(1H)-quinolone derivatives KIRIN BEER KABUSHIKI KAISHA (JP) 1989-11-29 EP disclosed
EP-0330340-A1 Therapeutic agents The Boots Company PLC (GB) 1989-08-30 EP disclosed
WO-1989007593-A1 THERAPEUTIC AGENTS THE BOOTS COMPANY PLC (GB) 1989-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142998-A1 Methods of making indazoles NAT1, CYP3A5, ALDH3A1 JAK2 3197/4885JAK1 2140/4885FABP4 3859/4885
US-20080146616-A1 Indoles Useful in the Treatment of Inflammation IDO1, PTGS1, PTGER1 JAK2 349/4885JAK1 824/4885FABP4 1807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.